stockrow
Saturday 7 November 2026
Export JAGX’s income statement to Excel — free account
Jaguar Animal Health, Inc.
JAGX Healthcare Biotechnology
Jaguar Animal Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.5 million, down 1.52% from fiscal 2024.
- Revenue
- −58.9%
- EPS
- +95.6%
- Free cash flow
- +13.8%
- Total debt
- −83.9%
Quarter to June 2026, against a year earlier
0.40
0.01
−2.44%
Follow JAGX
Alert me
Jaguar Animal Health, Inc. (JAGX) P/E ratio
Jaguar Animal Health, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 5,715,103× (December 2020) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
Low 0.0×
High 5,715,103×
Ten-year median
0.0×
Current reading's percentile
98
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BBLG Bone Biologics Corp. compare | n/m |
| BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR compare | n/m |
| ARTL Artelo Biosciences, Inc. compare | n/m |
| MTNB Matinas Biopharma Holdings, Inc. compare | n/m |
| SPRC SciSparc Ltd. compare | n/m |
| VBIO Valion Bio, Inc. compare | n/m |
| JAGX Jaguar Animal Health, Inc. | n/m |
| BPTH Bio-Path Holdings, Inc. compare | n/m |
| LNAI Lunai Bioworks Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)